疑难病杂志2018，Vol.17Issue(3)：243-246,4.DOI:10.3969/j.issn.1671-6450.2018.03.007
多受体途径联用药物治疗难治性膀胱过度活动症的多中心临床疗效观察
Tolterodine combined with doxazosin and imipramine treating refractory overactive bladder: a multicenter clinical trial
摘要
Abstract
Objective To explore the efficacy and safety of tolterodine with doxazosin and imipramine in patients with refractory overactive bladder (OAB). Methods A multicenter clinical study was conducted. 97 patients with refractory overactive bladder were treated with tolterodine,hdoxazosin and imipramine for 60 days. Before and after treatment,overactive bladder symptom score (OABSS) and urodynamic (UD) were recorded. Results After 60d combined treatment,the total effect rate was 87.6%(85/97).Before and after treatment,all patients had significant improvement in OAB symptoms evalua-ting by OABSS[(11.8 ± 2.8)vs. (6.4 ± 1.7),t=5.91,P<0.001]. Objective data from UD showed that the mean maxi-mum bladder capacity ranged from (189 ± 93)ml to(301 ± 39)ml(t=3.02,P=0.003)with treatment.the VFC increased from(123 ± 57)ml to(272 ± 75)ml(t=2.98,P=0.004).Uninhibited contractile wave of detrusor decreased from(4.1 ± 2. 7)to(0.9 ± 1.1)(t=3.47,P=0.001),the peak value decreased from(64.1 ± 22.8)cm H2O to(40.4 ± 17.2)cm H2O(t=2.91,P=0.005). Main side effects including 23 cases(23.7%) with dry mouth,3 cases(3.1%) with constipation,2 cases (2.1%) with transient hypotension,no patients abandon treatment due to side-effects. Conclusion Tolterodine combined with doxazosin and Imipramine can be an effective,it is safe method for refractory overactive bladder.关键词
药物治疗/膀胱过度活动症/难治性/尿动力学/多中心临床观察Key words
Pharmacotherapy/Overactive bladder/Refractory/Urodynamic/Multi-center clinical trial引用本文复制引用
王瑜,陈小刚,赵纯雄,姚兵,韩明..多受体途径联用药物治疗难治性膀胱过度活动症的多中心临床疗效观察[J].疑难病杂志,2018,17(3):243-246,4.基金项目
武汉市中青年医学骨干人才专项基金(武卫生计生[2014]77号) （武卫生计生[2014]77号）
